Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | CA7 | P43166 | 3/20 | 0.58 |
| ▸ | CA9 | Q16790 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | AGER | Q15109 | 1/20 | 0.44 |
| ▸ | CASR | P41180 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | TK1 | P04183 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096481 | 1.00 | CA1 (0.61) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL537424 | 1.00 | CA1 (0.61) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL8717149 | 0.89 | CA1 (0.53) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL4186642 | 0.86 | CA1 (0.49) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL4186639 | 0.86 | CA1 (0.49) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL2111572 | 0.86 | KIF11 (0.50) | CA1CA2CA7CA9TSHR | |
| SCHEMBL397022 | 0.84 | CA1 (0.78) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL4284462 | 0.81 | CA1 (0.51) | CA1CA2CA7CA9TSHR | |
| SCHEMBL7153591 | 0.81 | CA1 (0.76) | CA1CA2CA7CA9MAPK1 | |
| SCHEMBL3521030 | 0.81 | CA1 (0.45) | CA1CA2CA7CA9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186456-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2025-06-12 | — | — | US | disclosed |
| US-9206206-B2 | Oxidized lipid compounds and uses thereof | VASCULAR BIOGENICS LTD. (IL) | 2015-12-08 | — | — | US | disclosed |
| EP-2826370-A2 | Oxidized lipid compounds and uses thereof | Vascular Biogenics Ltd. (IL) | 2015-01-21 | — | — | EP | disclosed |
| EP-2826369-A2 | Oxidized lipid compounds and uses thereof | Vascular Biogenics Ltd. (IL) | 2015-01-21 | — | — | EP | disclosed |
| EP-2348866-B1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD (IL) | 2015-01-07 | — | — | EP | disclosed |
| US-20130203707-A1 | Oxidized Lipid Compounds and Uses Thereof | VASCULAR BIOGENICS LTD. (IL) | 2013-08-08 | — | — | US | disclosed |
| CN-102271517-A | oxidized lipid compounds and uses thereof | — | 2011-12-07 | — | — | CN | disclosed |
| US-20110207703-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD. (IL) | 2011-08-25 | — | — | US | disclosed |
| US-5476863-A | Inhibitors of platelet activating factor and diseases caused thereby; stability | EISAI CO., LTD. (JP) | 1995-12-19 | — | — | US | disclosed |
| US-5476864-A | Therapy for diseases caused by platelet activation factor | EISAI CO., LTD. (JP) | 1995-12-19 | — | — | US | disclosed |
| US-5273985-A | A 1-phenylaminocarbonyl-2-sulfoamidophenyleneamino-3-pyrid-2-ylaminocarbonyl glyceride | EISAI CO., LTD. (JP) | 1993-12-28 | — | — | US | disclosed |
| US-5187293-A | Blood platelet activating factor inhibitors | HOFFMANN-LA ROCHE INC. (US) | 1993-02-16 | — | — | US | disclosed |
| US-5057530-A | For inhibiting blood platelet activating faactors | HOFFMANN-LA ROCHE INC. (US) | 1991-10-15 | — | — | US | disclosed |
| US-5037827-A | Useful for treatment of disease caused by platelet activating factory | EISAI CO., LTD. (JP) | 1991-08-06 | — | — | US | disclosed |
| EP-0353474-A2 | Glycerin derivative and its pharmacological use | Eisai Co., Ltd. (JP) | 1990-02-07 | — | — | EP | disclosed |
| US-4863941-A | PLATELET ACTIVATING FACTOR INHIBITORS, ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0147768-B1 | GLYCERIN DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1989-02-08 | — | — | EP | disclosed |
| US-4731373-A | BLOOD PLATELET ACTIVATING FACTOR | HOFFMAN-LA ROCHE INC. (US) | 1988-03-15 | — | — | US | disclosed |
| EP-0208932-A2 | Glycerin derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1987-01-21 | — | — | EP | disclosed |
| EP-0147768-A2 | Glycerin derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1985-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186456-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | KRAS, NRAS, TP53 | CA1 3584/4885CA2 3018/4885CA7 1870/4885 |
| US-20130203707-A1 | Oxidized Lipid Compounds and Uses Thereof | LPO, GPX4, ALOX15B | CA1 3989/4885CA2 3456/4885CA7 2787/4885 |
| US-20110207703-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | LPO, GPX4, ALOX15B | CA1 3989/4885CA2 3456/4885CA7 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.